The World Health Organization (WHO) has issued a strong recommendation for ritonavir, marketed as Paxlovid, for mild and moderate COVID-19 individuals at high risk of hospitalization, calling it the best therapeutic option available. However, in low- and middle-income nations, availability, lack of pricing transparency in bilateral agreements established by the producer, and the necessity for rapid and correct testing before delivering it are making this life-saving treatment a huge obstacle
Individuals with non-severe COVID-19 who are at the highest risk of developing severe disease and hospitalization, such as unvaccinated, elderly, or immunosuppressed patients, should use Pfizer's oral antiviral medication
New results from two randomized controlled trials involving 3078 participants support this recommendation. According to the research, this treatment reduces the likelihood of hospitalization by 85 percent. This translates to 84 fewer hospitalizations per 1000 individuals in a high-risk category (above 10% probability of hospitalization).
The WHO advises against using it in low-risk patients because the advantages have been demonstrated to be insignificant.
One challenge for low- and middle-income nations is that the treatment can only be given while the disease is still in its early stages; consequently, timely and precise testing is critical for a favorable outcome with this therapy. According to data gathered by FIND, the average daily testing rate in low-income nations is one-eighth that of high-income countries. The global distribution of this medicine will rely heavily on improving access to early testing and diagnosis in primary health care settings.
WHO is afraid that, as with the COVID-19 vaccines, low- and middle-income countries will be put at the back of the line when it comes to receiving this treatment.
Due to the originating company's lack of openness, public health organizations are unable to gain an accurate picture of the medicine's availability, which nations are engaging in bilateral agreements, and what they are paying. Furthermore, Pfizer's license arrangement with the Medicines Patent Pool restricts the number of nations that can benefit from generic drug production.
The originator product, Paxlovid, will be added to the WHO prequalification list today, but generic products from quality-assured sources are still unavailable. Several generic businesses (many of which are covered by the Medicines Pool-Pfizer licensing deal) are in talks with WHO Prequalification, although it may take some time for them to meet international requirements and be able to supply the medicine abroad.
Pfizer should make its pricing and negotiations more transparent, and expand the geographic scope of its license with the Medicines Patent Pool so that additional generic manufacturers may start producing the medicine and make it available sooner and at lower prices, according to WHO.
In addition to the strong recommendation for ritonavir, WHO has upgraded its recommendation for remdesivir, an antiviral drug.
WHO has previously advised against using it in all COVID-19 patients, regardless of illness severity, because the evidence at the time indicated that it had little or no effect on mortality. WHO has amended its guideline following the publication of fresh data from a clinical trial looking at the outcome of hospital admission. Remdesivir is now recommended by the WHO for mild or moderate COVID-19 individuals who are at high risk of hospitalization.
The use of remdesivir in patients with severe or critical COVID-19 is now being reconsidered.
You must be logged in to post a comment.